中国P站

NDM-CRE infections refer to infections caused by New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (NDM-CRE). These bacteria are highly resistant to multiple classes of antibiotics, including carbapenems, which are often considered the last line of defense against severe bacterial infections. First identified in 2008, NDM-producing bacteria have rapidly spread worldwide, posing significant challenges to healthcare systems. Infections caused by NDM-CRE are associated with high morbidity and mortality, particularly in hospitalized and immunocompromised patients. The emergence of these multidrug-resistant organisms underscores the urgent need for robust surveillance, effective infection control, and development of new antimicrobial strategies [1, 2].

Discussion

NDM-CRE infections are primarily caused by Enterobacteriaceae such as Escherichia coli and Klebsiella pneumoniae, which carry the bla_NDM gene. This gene encodes the NDM enzyme, which deactivates carbapenem antibiotics and often coexists with other resistance genes, rendering bacteria resistant to multiple antibiotic classes. The infections can manifest as urinary tract infections, bloodstream infections, pneumonia, and wound infections, often progressing rapidly in vulnerable populations [3, 4].

Transmission occurs predominantly through person-to-person contact in healthcare settings, particularly when infection prevention measures are inadequate. Contaminated medical equipment, poor hand hygiene, and prolonged hospital stays increase the risk of NDM-CRE spread. Community-acquired cases, while less common, have also been reported, emphasizing the global reach of this threat [5, 6].

Diagnosis of NDM-CRE infections requires specialized laboratory testing. Standard culture methods, combined with molecular techniques like polymerase chain reaction (PCR), are used to detect the presence of the bla_NDM gene. Rapid and accurate identification is crucial for initiating appropriate infection control measures and selecting effective antimicrobial therapy. Treatment options are limited due to extensive drug resistance. Often, combination therapies using colistin, tigecycline, or newer beta-lactam/beta-lactamase inhibitor combinations are employed, though efficacy varies, and toxicity remains a concern [7, 8].

Prevention is paramount. Healthcare facilities implement strict infection control protocols, including isolation of infected patients, rigorous hand hygiene, environmental cleaning, and antimicrobial stewardship programs. Surveillance programs track the emergence and spread of NDM-CRE, guiding public health interventions. On a broader scale, global collaboration is essential to monitor outbreaks, share resistance data, and develop new antibiotics and alternative therapies such as bacteriophage therapy or immunotherapeutics [9, 10].

Conclusion

NDM-CRE infections represent a significant public health challenge due to their multidrug resistance, rapid spread, and high risk of severe outcomes. Effective management requires early detection, targeted antimicrobial therapy, stringent infection control, and robust surveillance systems. Beyond healthcare settings, global efforts to curb antimicrobial resistance, including responsible antibiotic use and the development of new treatment options, are essential. Addressing NDM-CRE infections is not only a clinical priority but also a critical step in combating the broader threat of multidrug-resistant bacteria and safeguarding the future of effective antimicrobial therapy.

References

1. Timmermans K, Kox M, Vaneker M, van den Berg M, John A, et al. (2016) . Intensive Care Med 42: 551-561.

   , ,

2. Timmermans K, Kox M, Scheffer GJ, Pickkers P (2016) . Shock 45: 108-16.

   , ,

3. Leijte GP, Custers H, Gerretsen J, Heijne A, Roth J, et al. (2018) . Front Immunol 9: 663.

   , ,

4. Hirsiger S, Simmen HP, Werner CM, Wanner GA, Rittirsch D, et al. (2012) Danger signals activating the immune response after trauma. Mediators Inflamm 2012: 315941.

   , ,

5. Eppensteiner J, Davis RP, Barbas AS, Kwun J, Lee J, et al. (2018) Front Immunol 9: 190.

   , ,

6. Leonard CA, Schoborg RV, Borel N (2015) PLoS One 10: 134943.

   , ,

7. Vénéreau E, Ceriotti C, Bianchi ME (2015) . Front Immunol 6:422.

   , ,

8. Feldman N, Rotter-Maskowitz A, Okun E (2015) . Ageing Res Rev 24: 29-39.

   , ,

9. Maslanik T, Mahaffey L, Tannura K, Beninson L, Greenwood BN, et al. (2013) . Brain Behav Immun 28: 54-62.

   , ,

10. Garg AD, Dudek AM, Agostinis P (2013) Biofactors 39: 355-367.

    , ,